Ivosidenib: A Review in Advanced Cholangiocarcinoma.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
accepted:
12
09
2023
medline:
23
11
2023
pubmed:
19
10
2023
entrez:
19
10
2023
Statut:
ppublish
Résumé
Ivosidenib (Tibsovo Cholangiocarcinoma (CCA) is often diagnosed at an advanced stage when the prognosis is poor due to limited treatment options, including standard-of-care (palliative) chemotherapy. Around 40% of patients with CCA have a tumor that can be targeted for treatment due to the presence of a molecular abnormality implicated in tumor formation and/or maintenance. One such abnormality (present in ≈14% of patients with intrahepatic CCA), is a mutated form of the isocitrate dehydrogenase 1 (IDH1) enzyme (‘mutant IDH1’) that inappropriately catalyses the production of 2-hydroxyglutarate (2-HG), an oncometabolite that promotes tumorigenesis. Ivosidenib (Tibsovo
Autres résumés
Type: plain-language-summary
(eng)
Cholangiocarcinoma (CCA) is often diagnosed at an advanced stage when the prognosis is poor due to limited treatment options, including standard-of-care (palliative) chemotherapy. Around 40% of patients with CCA have a tumor that can be targeted for treatment due to the presence of a molecular abnormality implicated in tumor formation and/or maintenance. One such abnormality (present in ≈14% of patients with intrahepatic CCA), is a mutated form of the isocitrate dehydrogenase 1 (IDH1) enzyme (‘mutant IDH1’) that inappropriately catalyses the production of 2-hydroxyglutarate (2-HG), an oncometabolite that promotes tumorigenesis. Ivosidenib (Tibsovo
Identifiants
pubmed: 37855990
doi: 10.1007/s11523-023-01002-3
pii: 10.1007/s11523-023-01002-3
doi:
Substances chimiques
ivosidenib
Q2PCN8MAM6
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
973-980Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127–40.
doi: 10.1016/j.annonc.2022.10.506
pubmed: 36372281
Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Gastroenterol Hepatol. 2020;17:557–88.
Rimini M, Puzzoni M, Pedica F, et al. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol. 2021;15(12):1367–83.
doi: 10.1080/17474124.2021.1991313
pubmed: 34669536
Lee Y-P, Oh SY, Kim KM, et al. Modified FOLFIRINOX as a second-line treatment for patients with gemcitabine-failed advanced biliary tract cancer: a prospective multicenter phase II study. Cancers (Basel). 2022;14(8):1950.
doi: 10.3390/cancers14081950
pubmed: 35454857
Adeva J, Sangro B, Salati M, et al. Medical treatment for cholangiocarcinoma. Liver Int. 2019;39(Suppl. 1):123–42.
doi: 10.1111/liv.14100
pubmed: 30892822
Cheng C-Y, Chen C-P, Wu C-E. Precision medicine in cholangiocarcinoma: past, present and future. Life. 2022;12(6):829.
doi: 10.3390/life12060829
pubmed: 35743860
pmcid: 9225212
Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitratdehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10(4):751–65.
doi: 10.21037/jgo.2019.03.10
pubmed: 31392056
pmcid: 6657309
Kendre G, Murugesan K, Brummer T, et al. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J Hepatol. 2023;78(3):614–26.
doi: 10.1016/j.jhep.2022.11.030
pubmed: 36528236
Makawita S, Borad MJ, Carapeto F, et al. IDH1 and IDH2 driven intrahepatic cholangiocarcinoma (IHCC): a comprehensive genomic and immune profiling study [abstract no. 4009]. J Clin Oncol. 2021;39(15 suppl):4009.
doi: 10.1200/JCO.2021.39.15_suppl.4009
Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739.
doi: 10.1038/nature08617
pubmed: 19935646
pmcid: 2818760
Wu M-J, Shi L, Merritt J, et al. Biology of IDH mutant cholangiocarcinoma. Hepatology. 2022;75(5):1322–7.
doi: 10.1002/hep.32424
pubmed: 35226770
Wu M-J, Shi L, Dubrot J, et al. Mutant IDH inhibits IFNγ-TET2 sgnaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. Cancer Discov. 2022;12(3):812–35.
doi: 10.1158/2159-8290.CD-21-1077
pubmed: 34848557
pmcid: 8904298
Notarangelo G, Spinelli JB, Perez EM, et al. Oncometabolite d-2HG alters T cell metabolism to impair CD8(+) T cell function. Science. 2022;377:1519–29.
doi: 10.1126/science.abj5104
pubmed: 36173860
pmcid: 9629749
Saatcioglu HD, Valle J, Macarulla T, et al. Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial [abstract no. 552]. J Immunother Cancer. 2022;10(Suppl 2):A576–7.
Saha SK, Parachoniak CA, Ghanta KS, et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature. 2014;513(7516):110–4.
doi: 10.1038/nature13441
pubmed: 25043045
pmcid: 4499230
Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300–5.
doi: 10.1021/acsmedchemlett.7b00421
pubmed: 29670690
pmcid: 5900343
Les Laboratoires Servier. Tibsovo (ivosidenib): EU prescribing information. 2023. https://www.ema.europa.eu/ . Accessed 30 Sept 2023.
Servier Pharmaceutical LLC. TIBSOVO (ivosidenib tablets), for oral use. 2022. https://www.accessdata.fda.gov/ . Accessed 30 Sept 2023.
Lowery MA, Burris HA 3rd, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(9):711–20.
doi: 10.1016/S2468-1253(19)30189-X
pubmed: 31300360
pmcid: 7934945
Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807.
doi: 10.1016/S1470-2045(20)30157-1
pubmed: 32416072
pmcid: 7523268
Aguado-Fraile E, Tassinari A, Ishii Y, et al. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. Future Oncol. 2021;17(16):2057–74.
doi: 10.2217/fon-2020-1274
pubmed: 33709779
European Medicines Agency. Tibsovo assessment report. 2023. https://www.ema.europa.eu/ . Accessed 30 Sept 2023.
Dai D, Yang H, Nabhan S, et al. Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects. Eur J Clin Pharmacol. 2019;75(8):1099–108.
doi: 10.1007/s00228-019-02673-6
pubmed: 31011758
Prakash C, Fan B, Altaf S, et al. Pharmacokinetics, absorption, metabolism, and excretion of [
doi: 10.1007/s00280-019-03793-7
pubmed: 30758648
Fan B, Dai D, Cohen M, et al. Effect of mild and moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of a single dose of oral ivosidenib in otherwise healthy participants. Clin Pharmacol Drug Dev. 2021;10(1):99–109.
doi: 10.1002/cpdd.821
pubmed: 32648303
Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669–77.
doi: 10.1001/jamaoncol.2021.3836
pubmed: 34554208
Zhu AX, Macarulla T, Javle MM, et al. Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation [abstract no. 266 plus presentation #GI21]. J Clin Oncol. 2021;39(3 Suppl.):266.
doi: 10.1200/JCO.2021.39.3_suppl.266
Chamberlain CX, Hua Z, Gliser C, et al. Longitudinal trends in health-related quality of life (HRQoL) among patients treated with ivosidenib (IVO) for IDH1-mutated cholangiocarcinoma (CCA) in the ClarIDHy study [abstract no 388 plus poster]. J Clin Oncol. 2022;40(4 Suppl.):388.
doi: 10.1200/JCO.2022.40.4_suppl.388
Abou-Alfa GK, Burris S, Adeva J, et al. Characterization of IDH-1 mutant cholangiocarcinoma patients who received ivosidenib treatment longer than a year [poster]. In: 10th Annual cholangiocarcinoma foundation conference, 2023.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Biliary Tract Cancers Version 2.2023—May 10, 2023. https://www.nccn.org/ . Accessed 30 Sept 2023.
Rimini M, Burgio V, Antonuzzo L, et al. Real-world data on ivosidenib in patients with previously treated isocitrate dehydrogenase 1-mutated intrahepatic cholangiocarcinomas: an early exploratory analysis. Target Oncol. 2022;17(5):591–6.
doi: 10.1007/s11523-022-00917-7
pubmed: 36114954
Reinbold R, Hvinden IC, Rabe P, et al. Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors. Nat Commun. 2022;13(1):4785.
doi: 10.1038/s41467-022-32436-4
pubmed: 35970853
pmcid: 9378673